US11091430 — Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
Method of Use · Assigned to Reata Pharmaceuticals Inc · Expires 2029-04-20 · 3y remaining
What this patent protects
This patent protects novel oleanolic acid derivatives and their uses, including pharmaceutical compositions and methods of using the compounds.
USPTO Abstract
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula:wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
Drugs covered by this patent
- Skyclarys (OMAVELOXOLONE) · Biogen Us
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3552 |
— | Skyclarys |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.